The Recall Desk
Severity pendingFDA (Drugs)·D-0029-2026·Announced 2025-10-22

CARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA, LEVODOPA AND ENTACAPONE)

Pending LLM rewrite. Source: FDA_DRUG D-0029-2026.

Severity not yet assessed

We have not scored this recall against our rubric yet, so we are not showing a severity rating or our usual guidance. The agency’s own notice below is the authoritative source — read it first.

Plain-English summary

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

The recalled product

Product
CARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA, LEVODOPA AND ENTACAPONE)
Brand
CARBIDOPA, LEVODOPA AND ENTACAPONE
Manufacturer
Rising Pharma Holding, Inc.

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # CS25070
  • exp. date 03/31/2027

UPCs (5)

  • 0316571690015
  • 0316571694013
  • 0316571692019
  • 0316571691012
  • 0316571693016

Distribution

Distributed nationwide across the United States.